This Insight Pharma Report reviews next-generation obesity drugs, including late-stage development programs as well as selected early-stage approaches to developing obesity drugs. It also discusses the obesity drug market, the need for novel drugs that are safe and truly effective, and the challenges in developing and commercializing such drugs.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
Obesity Drug Pipeline: Developing Therapies for a Complex Disease
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single user, single-site.